IL309453A - A method for quantifying individual antibodies from a mixture - Google Patents

A method for quantifying individual antibodies from a mixture

Info

Publication number
IL309453A
IL309453A IL309453A IL30945323A IL309453A IL 309453 A IL309453 A IL 309453A IL 309453 A IL309453 A IL 309453A IL 30945323 A IL30945323 A IL 30945323A IL 309453 A IL309453 A IL 309453A
Authority
IL
Israel
Prior art keywords
antibody
antibodies
protein
quantitating
hic
Prior art date
Application number
IL309453A
Other languages
English (en)
Hebrew (he)
Inventor
Dingjiang Liu
Lin Luo
Long Xu
Original Assignee
Regeneron Pharma
Dingjiang Liu
Lin Luo
Long Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dingjiang Liu, Lin Luo, Long Xu filed Critical Regeneron Pharma
Publication of IL309453A publication Critical patent/IL309453A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/102—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
IL309453A 2016-08-16 2017-08-08 A method for quantifying individual antibodies from a mixture IL309453A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375887P 2016-08-16 2016-08-16
PCT/US2017/045855 WO2018034885A1 (en) 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture

Publications (1)

Publication Number Publication Date
IL309453A true IL309453A (en) 2024-02-01

Family

ID=59702834

Family Applications (2)

Application Number Title Priority Date Filing Date
IL309453A IL309453A (en) 2016-08-16 2017-08-08 A method for quantifying individual antibodies from a mixture
IL264631A IL264631B2 (en) 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264631A IL264631B2 (en) 2016-08-16 2017-08-08 Methods for quantitating individual antibodies from a mixture

Country Status (15)

Country Link
US (5) US11020686B2 (enExample)
EP (2) EP3500297A1 (enExample)
JP (3) JP2019529350A (enExample)
KR (3) KR102511050B1 (enExample)
CN (2) CN109641050A (enExample)
AU (2) AU2017312785B2 (enExample)
BR (1) BR112019000872A2 (enExample)
CA (1) CA3031742A1 (enExample)
EA (1) EA201990317A1 (enExample)
IL (2) IL309453A (enExample)
MX (1) MX2019000935A (enExample)
MY (2) MY198401A (enExample)
SG (1) SG11201900201YA (enExample)
WO (1) WO2018034885A1 (enExample)
ZA (1) ZA201900350B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
WO2020113047A1 (en) * 2018-11-30 2020-06-04 Actinium Pharmaceuticals, Inc. Antibodies conjugated with actinium-225 and actinium-227, and related compositions and methods
US11486864B2 (en) * 2019-01-16 2022-11-01 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CA3174665A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
US11999777B2 (en) 2020-06-03 2024-06-04 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
CN114577885B (zh) * 2020-12-01 2024-03-29 齐鲁制药有限公司 一种检测重组组合抗体含量比例、电荷异质性和/或等电点的方法
TW202321292A (zh) 2021-07-14 2023-06-01 美商再生元醫藥公司 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
WO2025049384A1 (en) * 2023-08-31 2025-03-06 Amgen Inc. Methods for analyzing antibody co-formulations

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1996025425A1 (en) 1995-02-16 1996-08-22 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
EP0964057B1 (en) 1998-05-11 2004-12-22 Tosoh Corporation Method for separating nucleic acids by means of liquid chromatography
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
AU2003272368C1 (en) 2002-09-13 2009-07-23 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
SE0300612D0 (sv) * 2003-03-05 2003-03-05 Amersham Biosciences Ab A method of preparing ligands for hydrophobic interaction chromatography
WO2004087761A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
NZ548126A (en) 2004-02-27 2009-10-30 Ge Healthcare Bio Sciences Ab A process for the purification of antibodies involving addition of a second resin
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060027454A1 (en) 2004-08-09 2006-02-09 Dinovo Augustine Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
JP5064225B2 (ja) 2004-10-21 2012-10-31 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 抗体精製法
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
US20080299671A1 (en) 2005-12-02 2008-12-04 Ge Healthcare Bio-Sciences Ab Hydrophobic Interaction Chromatography
MX2008012295A (es) 2006-03-28 2008-10-09 Hoffmann La Roche Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
JP2010515020A (ja) * 2006-12-21 2010-05-06 ノバルティス アーゲー 抗体定量法
US20080299545A1 (en) 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
US8568586B2 (en) 2008-01-25 2013-10-29 Biogen Idec Ma Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
WO2010019814A1 (en) 2008-08-15 2010-02-18 Biogen Idec Ma Inc. Methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
ES2693194T3 (es) 2009-06-16 2018-12-10 Genzyme Corporation Métodos mejorados para la purificación de vectores de AAV recombinantes
BR112012001843A2 (pt) * 2009-07-30 2016-03-15 Hoffmann La Roche separador de coluna de cromatografia móvel
WO2011028961A2 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP3037104B1 (en) 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
CA2787897A1 (en) 2010-02-12 2011-08-18 Dsm Ip Assets B.V. Single unit antibody purification
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
JP6088435B2 (ja) 2010-12-15 2017-03-01 バクスアルタ ゲーエムベーハー 導電率グラディエントを用いる溶出液収集
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
CA2853011C (en) 2011-10-19 2022-09-06 Novimmune S.A. Methods of purifying antibodies
US20140288278A1 (en) 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
MX350355B (es) 2011-11-14 2017-09-04 Regeneron Pharma Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
EP2782932A1 (en) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
EP2791176B1 (en) 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US20130336957A1 (en) 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20150344557A1 (en) 2012-12-20 2015-12-03 Medlmmune, Llc Liquid Antibody Formulation With Improved Aggregation Properties
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN118388581A (zh) 2013-03-08 2024-07-26 建新公司 治疗性蛋白药物物质的整合连续制造
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP2975061A4 (en) * 2013-03-13 2017-03-01 Ibentrus Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
ES2834113T3 (es) 2013-03-15 2021-06-16 H Lundbeck As Purificación de anticuerpos y monitorización de la pureza
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
JP2016519070A (ja) * 2013-03-15 2016-06-30 アッヴィ・インコーポレイテッド 抗体薬物複合体（ａｄｃ）の精製
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
KR20160050062A (ko) 2013-09-05 2016-05-10 제넨테크, 인크. 크로마토그래피 재사용 방법
KR102373930B1 (ko) 2013-09-13 2022-03-11 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR20160055269A (ko) * 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
EP3060578A4 (en) 2013-10-25 2017-07-05 Medlmmune, LLC Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
JP2016088937A (ja) * 2014-10-31 2016-05-23 オーストリッチファーマ株式会社 エボラウイルスに対する抗体および抗体の製造方法
AU2015355150A1 (en) 2014-12-02 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an IL-6R antagonist
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
BR112018012801B1 (pt) 2015-12-22 2024-03-12 Regeneron Pharmaceuticals, Inc Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
MA44145A (fr) 2015-12-22 2018-10-31 Regeneron Pharma Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
EP3468981B1 (en) 2016-06-14 2024-07-24 Biogen MA Inc. Hydrophobic interaction chromatography for purification of oligonucleotides
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
WO2019040671A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
US20210009632A1 (en) 2018-03-29 2021-01-14 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
JP2021528425A (ja) 2018-06-19 2021-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ クロマトグラフィーを用いたタンパク質の精製方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20220267369A1 (en) 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
WO2020037016A1 (en) 2018-08-15 2020-02-20 Bristol-Myers Squibb Company Protein fragmentation control strategy by re-oxidation in downstream chromatography
WO2020096958A1 (en) 2018-11-05 2020-05-14 Bristol-Myers Squibb Company Method for purifying pegylated protein
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
ES2985015T3 (es) 2019-03-29 2024-11-04 Bristol Myers Squibb Co Métodos para medir la hidrofobicidad de resinas cromatográficas
CN114173827B (zh) 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法

Also Published As

Publication number Publication date
JP2024173983A (ja) 2024-12-13
US20230119592A1 (en) 2023-04-20
CN119119244A (zh) 2024-12-13
IL264631A (en) 2019-02-28
US20210031123A1 (en) 2021-02-04
US20210268404A1 (en) 2021-09-02
JP2019529350A (ja) 2019-10-17
KR20190039144A (ko) 2019-04-10
KR20230041834A (ko) 2023-03-24
BR112019000872A2 (pt) 2019-04-30
US20230415073A1 (en) 2023-12-28
EP4183414A1 (en) 2023-05-24
US11850535B2 (en) 2023-12-26
MY198401A (en) 2023-08-28
AU2017312785B2 (en) 2024-10-10
MY196321A (en) 2023-03-24
CN109641050A (zh) 2019-04-16
ZA201900350B (en) 2025-05-28
SG11201900201YA (en) 2019-02-27
IL264631B1 (en) 2024-01-01
US20190184312A1 (en) 2019-06-20
AU2017312785A1 (en) 2019-01-24
JP2022159388A (ja) 2022-10-17
US11571636B2 (en) 2023-02-07
KR20220025943A (ko) 2022-03-03
AU2025200089A1 (en) 2025-01-23
EA201990317A1 (ru) 2019-07-31
US11020686B2 (en) 2021-06-01
US11369896B2 (en) 2022-06-28
KR102369014B1 (ko) 2022-03-02
CA3031742A1 (en) 2018-02-22
KR102511050B1 (ko) 2023-03-17
MX2019000935A (es) 2019-07-04
EP3500297A1 (en) 2019-06-26
WO2018034885A1 (en) 2018-02-22
IL264631B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL309453A (en) A method for quantifying individual antibodies from a mixture
JP2019529350A5 (enExample)
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2020513786A5 (enExample)
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
WO2017193094A8 (en) Dna monoclonal antibodies targeting checkpoint molecules
JP2015146822A5 (enExample)
EP4464333A3 (en) Anti-death receptor antibodies and methods of use thereof
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
WO2010010467A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
FI2897981T3 (fi) Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä
SG10201906762YA (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
FI3390442T3 (fi) Anti-C5-vasta-aineita ja käyttömenetelmiä
NZ603619A (en) Antibodies that bind to il-12 and methods of purifying the same
HK1248721A1 (zh) 抗体分子及其用途
FI3426680T3 (fi) Aktiviini tyypin 2 reseptoriin sitoutuvat proteiinit ja niiden käytöt
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
MX2018005831A (es) Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
RU2016141285A (ru) Биспецифические антигенсвязывающие полипептиды
CN105241973B (zh) 蛋白制剂的高效液相色谱检测方法
HK1222871A1 (zh) 具有最小单体分离的重组多克隆抗体多聚体的分离
IL278323B1 (en) Antibodies directed against glycoprotein IV